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Anti-GD2Abstract Background: There is rising concern on the impact of new strategies, such as high-
dose chemotherapy (HDC) and immunotherapy, on the pattern of relapse in high-risk neuro-
blastoma (HR-NBL). Our aim is to evaluate the incidence and identify risk factors for first
recurrence in the central nervous system (CNS) in HR-NBL.
Patients and methods: Data from patients with stage 4V HR-NBL included from February
2002 to June 2015 in the prospective HR-NBL trial of the European International Society
of Pediatric Oncology Neuroblastoma Group were analysed. Characteristics at diagnosis,
treatment and the pattern of first relapse were studied. CNS imaging at relapse was centrally
reviewed.
Results: The 1977 included patients had a median age of 3 years (1 daye20 years); 1163 were
boys. Among the 1161 first relapses, 53 were in the CNS, with an overall incidence of 2.7%,
representing 6.2% of all metastatic relapses. One- and three-year post-relapse overall survival
was 25  6% and 8  4%, respectively. Higher risk of CNS recurrence was associated with
female sex (hazard ratio [HR] Z 2.0 [95% confidence interval {CI}: 1.1e3.5]; P Z 0.016),
MYCN-amplification (HR Z 2.4 [95% CI: 1.2e4.4]; P Z 0.008), liver (HR Z 2.5 [95% CI:
1.2e5.1]; P Z 0.01) or >1 metastatic compartment involvement (HR Z 7.1 [95% CI: 1.0
e48.4]; PZ 0.047) at diagnosis. Neither HDC nor immunotherapy was associated with higher
risk of CNS recurrence. Stable incidence of CNS relapse was reported over time.
Conclusions: The risk of CNS recurrence is linked to both patient and disease characteristics,
with neither impact of HDC nor immunotherapy. These findings support the current treat-
ment strategy and do not justify a CNS prophylactic treatment.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
High-risk neuroblastoma (HR-NBL) represents a major
clinical challenge in pediatric oncology. The introduc-
tion of high-dose chemotherapy (HDC) followed by
autologous stem cell rescue (ASCR) has increased sur-
vival rates [1e3]. However, long-term survival is still
poor, and around half of the patients relapse. Immu-
notherapy has further improved outcomes, but the long-
term impact still has to be evaluated [4e6].
There is a rising concern on the impact of new stra-
tegies (i.e. HDC regimens and immunotherapy) on the
pattern of relapse, especially taking into account that
anti-disialoganglioside (GD2) antibodies do not pene-
trate the bloodebrain barrier, potentially allowing the
central nervous system (CNS) to emerge as a sanctuary
site leading to a higher proportion of CNS recurrences
[7,8]. Few data have been reported in the literature on
the incidence of CNS relapse in this population [7e10].
The precise analysis of CNS recurrence is of major in-
terest, as it may impact the design of future HR-NBL
strategies.
The European Society of Paediatric Oncology Neu-
roblastoma Group initiated a multicentre, international,
randomised phase III trial (HR-NBL1/SIOPEN) that
recruited patients from 2002. This prospectivelycollected cohort provides a unique opportunity to
identify the incidence and risk factors of CNS recurrence
at first relapse in a well-characterised population.
Moreover, the analysis of this cohort permits the eval-
uation of the impact of different HDC regimens and the
administration of immunotherapy on the risk of CNS
involvement at recurrence.2. Patients and methods
2.1. Patients, disease and treatment features
Patients enrolled in the HR-NBL1/SIOPEN trial
(NCT00030719) from February 2002 to June 2015 with
newly diagnosed stage 4 HR-NBL, older than 12
months regardless of MYCN status or younger than 12
months with MYCN-amplified tumours, were included
in this analysis [11,12].
They received Rapid COJEC induction chemo-
therapy with or without top-
otecanevincristineedoxorubicin (TVD), continuing to
HDC followed by ASCR if they reached the ‘R1’ criteria
[13]: at least a 50% reduction in skeletal iodine-123-
meta-iodobenzylguanidine (MIBG) positivity and no
more than three residual positive spots, as well as
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patients were randomised to receive HDC with either
busulfanemelphalan (BueMel) or carboplatin/etopo-
side/melphalan (CEM). After 2010 BueMel became the
SIOPEN HDC standard of care following the outcome
of the randomised trial showing the significant benefit of
BueMel over CEM in this cohort of patients [13]. Local
treatment was to aim for complete primary tumour
resection, followed by radiotherapy (21 Gy) to the
tumor bed. Maintenance treatment was 13-cis retinoic
acid alone until 2010, after which it was combined with
immunotherapy (dinutuximab beta  interleukin-2).
The trial was approved by national regulatory au-
thorities and by national and institutional ethical com-
mittees. Parents or guardians of patients younger than
18 years and adult patients provided written informed
consent before enrolment.
Data regarding clinical presentation (age, sex, stage,
primary and metastatic sites), MYCN status, treatment
type (additional TVD, HDC regimen, maintenance
treatment), disease response at the end of induction,
before maintenance and at the end of treatment, follow-
up and first relapse were prospectively collected in the
HR-NBL1/SIOPEN database. Only first recurrences
were considered for this analysis. Cranial imaging was
not systematically requested in patients without MIBG-
avid skull metastases in the HR-NBL1/SIOPEN trial.
CNS relapse was defined as the appearance of a new
leptomeningeal or parenchymal lesion, excluding me-
tastases originating in the bone of the skull.
2.2. Central review of imaging
A secure web-based system, featuring automated de-
identification of DICOM images, was developed and
provided by the AIT Austrian Institute of Technology
within the frame of SIOPEN-R-NET, to perform
retrospective central imaging review. Brain computed
tomography (CT), brain/spine magnetic resonance im-
aging (MRI) and MIBG scans were requested for all
patients with identified CNS recurrence at first relapse.
Image gathering and uploading was organised in six
centres and, subsequently, centrally reviewed by a pe-
diatric radiologist (C.S.) and a nuclear medicine expert
(R.C.).
2.3. Statistical methods
Categorical variables were described with the numerical
count (percentage) of each category. Continuous vari-
ables were described as median, minimum and
maximum. Event-free survival (EFS) and overall sur-
vival (OS) [14] were estimated using the KaplaneMeier
method and compared by the log-rank test. For EFS,
relapses, progressions, death from any cause and sec-
ondary malignancies were considered as an event. For
OS, death from any cause was considered as an event.Patients without an event were censored at the date of
the last follow-up. The interval was from time of diag-
nosis and, for post-relapse survival, from the time of the
first relapse/progression. Cumulative incidences for
CNS relapses were estimated taking into account the
competing risk of non-CNS relapse/progression, death
from any cause and secondary malignancies [14]. Gray’s
method was used for the statistical comparison of cu-
mulative incidence, and multivariable analysis was per-
formed by the model of Fine and Gray [15]. For the
evaluation of HDC and maintenance treatment, the in-
terval starts with HDC and maintenance treatment,
respectively. A separate Fine and Gray model adjusted
for sex, age, MYCN, liver metastases and number of
metastatic components was performed to investigate the
impact of HDC on CNS-relapses. For the evaluation of
maintenance treatment, the model was additionally
adjusted for HDC. P < 0.05 was considered as statisti-
cally significant. Data were analysed using SAS 9.4.3. Results
In the HR-NBL1/SIOPEN trial, 1977 patients with
stage 4 HR-NBL were included in 170 centres from 19
countries. Of these, 1163 were boys. The median age at
diagnosis was 3.0 years (range: 1 daye20 years). Among
the whole cohort, 1161/1977 (59%) patients presented
with at least one relapse/progression before January
2016, with a median follow-up of 5.2 years (interquartile
range: 2.1e6.5 years). Of these, 855 had a metastatic
relapse (disseminated or combined), and 63 patients
were reported as presenting with CNS involvement at
first recurrence. Central review confirmed a CNS relapse
in 54/59 evaluable patients, which corresponds to 92% of
confirmed CNS relapses (95% confidence interval [CI]:
82e96%). One patient with a confirmed CNS relapse,
but not as first relapse, was not included in the CNS
cohort. The five patients for whom the CNS relapse was
not confirmed had skull bone relapses with intracranial
extension, with neither parenchymal nor leptomeningeal
involvement.
A final cohort of 53 confirmed CNS relapses as first
recurrence was considered in the CNS analysis popula-
tion (Figure 1; Supplementary Table 1). Among patients
with stage 4 HR-NBL, the incidence of CNS relapse
represented 2.7% of the whole cohort and 6.2% of the
metastatic relapses.3.1. Clinical and radiological features of CNS relapses
The median time to CNS recurrence from diagnosis was
1.0 year (range: 0.2e2.5 years), compared with 1.2 years
(range: 0.02e8.3 years) for relapses at other sites
(p Z 0.05). Most of the CNS relapses (90%) were
diagnosed based on neurological symptoms (intracranial
Fig. 1. The HR-NBL1/SIOPEN patients’ recurrences flowchart. CNS: central nervous system.
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the end of treatment (39/53; 74%).
Brain MRI/CT scans were performed at diagnosis in
14/53 patients; only two of these presented with CNS
involvement at primary diagnosis. A complete disease
evaluation at relapse was performed in 40/53 patients,
revealing isolated CNS relapse in 18/40 patients (45%)
and combined relapse, mainly bone involvement, in 22/
40 patients (55%). CNS lesions were mainly supra-
tentorial, presenting as a unique lesion in half of the
patients (Supplementary Figure 1). Leptomeningeal
disease was found in 7/27 evaluable patients. The main
reason for lack of neuroaxis imaging was rapidly disease
progression with clinical deterioration. The MIBG scan
at the time of relapse was available for a central review
in 10/53 patients, and CNS metastases could be identi-
fied on MIBG scan in 6/10 patients.3.2. Outcome of patients with CNS relapse at first
recurrence
Eighteen of 53 patients did not receive any treatment at
relapse because of rapidly disease progression(Figure 2). Twenty-seven patients were treated with
chemotherapy, mainly temozolomide-containing regi-
mens (22/27). Thirteen patients underwent surgery of the
CNS lesion(s). Radiotherapy was performed in 18 pa-
tients, with cranio-spinal irradiation in 10 of them.
Post-relapse one-year and three-year OS was 25  6%
and 7  4%, respectively. Median survival time after the
diagnosis of the CNS recurrence was 4 months (range:
0e82 months). Although the short-term survival of pa-
tients with CNS relapse after the end of treatment was
longer than for those with earlier CNS relapse (post-
relapse one-year OS: 45  11% versus 12  6%,
p Z 0.026), long-term survival rates were similarly poor
(post-relapse three-year OS: 10  7% versus 6  4%)
(Supplementary Figure 2). Patients with isolated CNS
recurrence had a better outcome (p Z 0.007) than those
with a combined relapse (Figure 3A). Post-relapse one-
year OS was worse for children with CNS recurrence
than patients with relapses to other sites (p < 0.002),
although long-term survival was as poor for both groups
(Figure 3B). Among those patients for whom at least
one treatment modality was applied (n Z 31), three
patients were alive with a follow-up of 4.7, 4.9 and 10.1
Fig. 2. The flowchart of second-line treatment and outcome of patients with CNS recurrences at first relapse. CNS: central nervous system,
CT: chemotherapy, SX: surgery, RT: radiotherapy.
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tients presented with a single CNS lesion without any
further metastatic involvement and were treated with
complete surgical excision, cranio-spinal radiotherapy,
and all but one received second-line chemotherapy with
a temozolomide-containing regimen.
3.3. Risk factors of CNS relapse in stage 4 HR-NBL
In the univariate analysis, MYCN amplification (4  1%
versus 2  0%, p Z 0.005), liver involvement (8  2%
versus 2  0%, p < 0.001), and >1 metastatic system/
compartment (3  0% versus 0  0%, p Z 0.048) at
diagnosis (Table 1) were significantly associated with a
higher incidence of CNS relapse. No significant impact
on the incidence of CNS relapse was shown in accor-
dance with the HDC regimen (BueMel, n Z 819 versus
CEM, n Z 253), with a CNS incidence of 3  1% versus
3  1% (p Z 0.831), respectively (Table 1;
Supplementary Figure 4A). The administration of
dinutuximab beta (n Z 350) did not significantly influ-
ence the risk of CNS recurrence when compared withFig. 3. Post-relapse overall survival (OS) of A) patients with central ne
at first relapse B) patients with stage IV high-risk neuroblastoma in aretinoic acid only (3  1% versus 3  1%, p Z 0.983)
(Supplementary Figure 4B), and the administration of
IL-2 had no impact on the incidence of CNS recurrence
(p Z 0.88) (data not shown). The incidence of CNS
recurrence did not increase in patients registered before
and after 2009 (3  1% versus 3  1%, respectively;
p Z 0.486), being 2010 the year when dinutuximab beta
was introduced into the HR-NBL1 trial (Supplementary
Figure 4C).
In the multivariate analysis, female sex (sub-
distribution hazard ratio evaluating hazards for CNS
relapses taking into account the competing events
[sHR]: 2.0 [1.1e3.5]; p Z 0.016), MYCN status (sHR:
2.4 [1.2e4.4]; p Z 0.008), hepatic (sHR: 2.5 [1.2e5.1].
p Z 0.013) and >1 metastatic system/compartment
involvement (sHR: 7.1 [1.0e48.4]; p Z 0.047) were in-
dependent significant risk factors (Table 1) at diagnosis.
On the other hand, adjusted for sex, age, liver metas-
tases and number of metastatic compartments, no
impact of the HDC regimen (sHR: 0.9 [0.4e2.1];
p Z 0.787) was found. The same was true when the
impact of immunotherapy adjusted for these prognosticrvous system (CNS) recurrence, according to the disease extension
ccordance with the site of relapse.
Table 1
Comparison of patients and disease’s characteristics at diagnosis as well as treatment features for patients with stage 4 neuroblastoma with and
without CNS relapse (univariate and multivariate analysis).
Patients Univariate analysis p-value Multivariate analysis
CNS relapses Event-free survival CNS relapses
Events 5-year CI p-value Events 5-year EFS sHR (95% CI) p-value
A) Risk factors at diagnosis
Sex Male 1163 25 0.02  0.00 0.077 729 0.32  0.02 0.293 1 0.016
Female 814 28 0.04  0.01 517 0.30  0.02 2.0 (1.1e3.5)
Age <1 year 98 6 0.07  0.03 0.111 47 0.45  0.06 0.011 1
1e1.5 yrs 191 5 0.03  0.01 100 0.44  0.04 0.6 (0.1e2.1) 0.377
1.5e5 yrs 1277 34 0.03  0.00 801 0.32  0.01 0.7 (0.3e1.9) 0.501
>5 yrs 411 8 0.02  0.01 298 0.20  0.02 0.67 (0.2e2.4) 0.539
MYCN status MNA 1090 20 0.02  0.00 0.005 698 0.29  0.02 0.265 1
MNAþ 738 30 0.04  0.01 459 0.33  0.02 2.4 (1.2e4.4) 0.008
Metastatic sites e
BM  376 7 0.02  0.01 0.231 190 0.46  0.03 <0.001
þ 1497 45 0.03  0.00 1002 0.27  0.01
Skeleton  311 8 0.03  0.01 0.767 172 0.40  0.03 0.016 e
þ 1545 45 0.03  0.00 1000 0.30  0.01
Liver  1599 37 0.02  0.00 <0.001 102 0.31  0.01 0.042 1
þ 225 16 0.08  0.02 148 0.28  0.03 2.5 (1.2e5.1) 0.013
Pulmonary  1686 47 0.03  0.00 0.895 1071 0.31  0.01 <0.001 e
þ 134 4 0.03  0.02 226 0.22  0.04
Meta. Comp. 1 222 1 0.00  0.00 0.048 330 0.49  0.04 <0.001 1
>1 1546 50 0.03  0.00 1016 0.29  0.01 7.1 (1.0e48.4) 0.047
Time period <2009 1015 26 0.03  0.01 0.486 735 0.28  0.01 0.003 e
2009 962 27 0.03  0.01 511 0.34  0.02
B) Treatments
High-dose therapy BUMEL 819 24 0.03  0.01 0.831 432 0.42  0.02 <0.001 0.9 (0.4e2.1)a 0.787
CEM 253 7 0.03  0.01 181 0.30  0.03
Maintenance Retinoic acid 522 14 0.03  0.01 0.983 322 0.38  0.02 <0.001 1.1 (0.4e2.8)b 0.817
Immunotherapy 350 9 0.03  0.01 132 0.54  0.03
CEM: carboplatin/etoposide/melphalan; CI: confidence interval; CNS: central nervous system; BM: bone marrow; Meta. Comp: number of
metastatic components; CI: confidence interval; sHR: subdistribution hazard ratio evaluating hazards for CNS relapses taking into account the
competing events; EFS: event-free survival.
a Adjusted for sex, age, MYCN, liver metastases and number of metastatic components.
b Adjusted for sex, age, MYCN, liver metastases, number of metastatic components and HDC.
P. Berlanga et al. / European Journal of Cancer 144 (2021) 1e86factors and HDC (sHR: 1.1 [0.4e2.8]; p Z 0.817) was
evaluated.
4. Discussion
Few and discordant data have been reported so far in
the literature on the incidence of CNS relapse in patients
with HR-NBL, and some of them suggested an
increased rate of CNS involvement over time [7e10].
The Children’s Oncology Group (COG) confirmed CNS
relapses at first recurrence in 8 (2%) of 434 patients older
than 12 months with stage 4 neuroblastoma that were
registered in the COG3891 protocol from 1991 to 1996
[9]. In a French retrospective analysis of 434 children
with stage 4 neuroblastoma diagnosed between 1985 and
2000, disease progression occurred in 225 patients,
including 23 patients (5%) with radiologically confirmed
metastases at the CNS at first recurrence [10]. Among
the 127 patients with stage 4 neuroblastoma diagnosed
at Memorial Sloan Kettering (MSK) between 1980 and
1999, eight patients (6%) developed confirmed CNSrelapses. In this cohort, the incidence of CNS metastases
seemed to be more frequent in patients previously
treated with immunotherapy and no HDC (7/67), in
comparison with patients that received HDC and no
immunotherapy (1/60) [7]. According to the German
experience, CNS relapses were reported in 49 (11%) of
451 patients with HR-NBL (stage 4, stage 3 MYCN-
amplified tumours) treated with HDC as part of the
first-line treatment from 1990 to 2007 [8]. A central re-
view of imaging was not reported. Although some of
these patients had previously received anti-GD2 as part
of the maintenance therapy, no separate analysis of the
two populations treated with or without immuno-
therapy was done.
In our cohort, the incidence of CNS relapse repre-
sented 2.7% of the total number of relapses and 6.2% of
the metastatic relapses. The reported incidence of CNS
recurrences at first relapse is similar to the COG expe-
rience [9] but lower than in other reports [7,8,10]. This
may be partially explained by the smaller patient co-
horts of previous studies and by the lack of a central
P. Berlanga et al. / European Journal of Cancer 144 (2021) 1e8 7review of imaging. However, the incidence of CNS re-
currences at first relapse in our cohort may also be
underestimated. It is important to highlight that cranial
imaging was not requested in patients without MIBG-
avid skull metastases in the HR-NBL1/SIOPEN trial;
therefore, it may have been selectively performed in
symptomatic patients only. Nevertheless and most
importantly, our results do not confirm a trend towards
a higher proportion of CNS recurrences over time, as
suggested in previous reports as a result of better control
of other metastatic sites and lack of anti-GD2 anti-
bodies bloodebrain barrier penetrance [7,8]. Indeed,
neither the HDC regimen nor the use of immunotherapy
was associated with a higher risk of CNS involvement at
first relapse. On the contrary, patient and disease fea-
tures at diagnosis, such as female sex, MYCN amplifi-
cation, hepatic and >1 metastatic system/compartment
involvement, were identified as significant risk factors
for CNS relapse. Only two of the previously published
studies performed an analysis of prognostic factors for
CNS relapse and univariate analyses showed that LDH
and lumbar puncture at diagnosis [7], or age, lumbar
puncture at diagnosis and MYCN-amplification [10]
were risk factors for CNS recurrence. Concerning lum-
bar puncture, this is not recommended in the HR-
NBL1/SIOPEN trial; therefore this information is not
captured in the database and could not be analysed.
Nevertheless, as lumbar puncture at diagnosis might be
performed in patients with neurological symptoms, it
seems a likely source of bias rather than a real risk factor
of CNS involvement.
Post-relapse OS of patients with CNS recurrence is
extremely poor (post-relapse first-year and three-year of
OS of 25  6% and 7  4%), although long-term sur-
vival was equally poor in relapses to other sites.
Nevertheless, in our cohort 3/17 patients with isolated
CNS relapses who were treated with complete surgery,
cranio-spinal radiotherapy and chemotherapy, mainly
temozolomide-containing regimens, are long-term
survivors.
In the St. Jude Children’s Research Hospital experi-
ence, four of 10 children with CNS relapse treated be-
tween 1978 and 1989 received cranio-spinal
radiotherapy (surgery and chemotherapy), and two of
them were alive and free of disease at 50 and 62 months
after CNS relapse [16]. In another retrospective analysis
of 29 patients with CNS relapses treated in the MSK
between 1987 and 2007, none of the patients treated
before 2003 with focal radiotherapy survived, although
12 of 16 patients treated with surgical resection, cranio-
spinal irradiation with irinotecan as radiosensitizer,
followed by irinotecanetemozolomide  carboplatin
and intrathecal radio-iodinated monoclonal antibodies
(3F8 or 8H9), were alive without CNS disease with a
median of 28 months of follow-up [7,17]. This higher
survival may be at least partially explained by a selection
bias, as patients with CNS relapses receiving multimodaltreatment are a population with better prognosis as
shown in our cohort.
In conclusion, this study provides data on the inci-
dence, risk factors and outcome of CNS recurrence at
first relapse in a large, prospective and unselected cohort
of patients with HR-NBL. Our results do not show a
trend toward an increasing risk of CNS recurrence over
time, nor do they display a significant impact of the
HDC regimen or immunotherapy, thus not justifying a
change in the current treatment strategy. Moreover, the
low incidence of CNS recurrence in our population does
not seem to justify prophylactic treatment in future tri-
als either. Finally, it is important to underline that long-
term survival can still be achieved, mainly in patients
with isolated CNS relapse. It will be of major impor-
tance to identify future strategies that might help to
achieve an earlier diagnosis of non-symptomatic CNS
involvement to allow adequate multimodal treatment.Author contribution statement
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